Search

Your search keyword '"Shoji H"' showing total 1,937 results

Search Constraints

Start Over You searched for: Author "Shoji H" Remove constraint Author: "Shoji H"
1,937 results on '"Shoji H"'

Search Results

1. Exposure to Maternal Immune Activation Causes Congenital Unfolded Protein Response Defects and Increases the Susceptibility to Postnatal Inflammatory Stimulation in Offspring

2. Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016

3. OGLE-2018-BLG-1185b : A Low-Mass Microlensing Planet Orbiting a Low-Mass Dwarf

4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

8. Unique bone histology of modern giant salamanders: a study on humeri and femora of Andrias spp.

10. 1244P Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)

11. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

12. 1217P Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)

13. 1465P Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy

15. 1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)

16. 522P Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)

17. 518MO Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)

20. P-61 Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy

21. PD-3 Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial

22. Evaluation of bovine embryo quality based on gene expression profiling using whole-transcriptome amplification

23. Predictive biomarkers of COVID-19 prognosis identified in Bangladesh patients and validated in Japanese cohorts

24. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

25. Surgeons' fear of getting infected by COVID19: A global survey

27. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

28. Surgeons' fear of getting infected by COVID19: A global survey

30. Molecular basis promoting centriole triplet microtubule assembly

31. Cerebrospinal fluid analysis Clinical neurochemistry

32. Increased deadwood carbon stocks through planted forestry practices: insights from a Forest Inventory Survey in Japan

33. OGLE-2018-BLG-1185b: A Low-mass Microlensing Planet Orbiting a Low-mass Dwarf

34. SO-19 A multicenter phase Ⅱ trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial

35. O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial

36. P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial

37. OGLE-2018-BLG-1185b:A Low-mass Microlensing Planet Orbiting a Low-mass Dwarf

39. 1554P Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2- positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapy

42. Divergent data-driven estimates of global soil respiration

46. P-87 A multi-institutional observational study evaluating the efficacy of anti-epidermal growth factor antibody re-challenge in tissue RAS/BRAF wild-type metastatic colorectal cancer

47. P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

50. Screening policies, preventive measures and in-hospital infection of COVID-19 in global surgical practices

Catalog

Books, media, physical & digital resources